

Drozitumab

Cat. No.:	HY-P99286
CAS No.:	912628-39-8
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma ^{[1][2][3]} .
In Vitro	Drozitumab selectively eliminates cancer stem cells (CSCs), resulting in tumor growth inhibition and even regression of pancreatic tumors ^[3] . Drozitumab induces apoptosis in mesenchymal TNBC cell lines but not in cell lines from other breast cancer subtypes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Dine JL, et al. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. *Breast Cancer Res Treat.* 2016 Jan;155(2):235-51.

[2]. Kang Z, et al. Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. *Clin Cancer Res.* 2011 May 15;17(10):3181-92.

[3]. Eng JW, et al. Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5. *J Immunother Cancer.* 2016 Jun 21;4:33.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA